Travere Therapeutics (TVTX) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$0.37
- EPS estimate
- −$0.13
- EPS surprise
- −174.68%
- Revenue surprise
- +7.83%
- Revenue
- $169.6M
- Revenue estimate
- $157.3M
- Reported
- Aug 4, 2026
Travere Therapeutics reported Q2 2026 results on August 4, 2026. It posted a loss of $0.37 per share, wider than the expected loss of $0.13, a 174.68% miss. Revenue was $169.6 million, about 8% above the $157.3 million consensus. Compared with Q2 2025, the loss widened from $0.14 per share, while revenue rose about 79% from $94.8 million.
Losses run through most of the table. Travere lost money in 17 of the last 20 quarters, with annual losses of $4.37 per share in 2022, $1.61 in 2023 and $4.10 in 2024. The three profitable quarters were Q3 2023 at $1.97, Q3 2025 at $0.28 and Q4 2025 at $0.03. That brought the 2025 loss down to $0.30 per share. Revenue was roughly flat at $193 million to $232 million a year from 2022 to 2024, then about doubled to $465.3 million in 2025. Q2 2026 is the revenue high in the table. Travere beat the EPS estimate 6 times in 20 quarters.
The company reported Q3 between October 27 and November 7 in each of the past five years. That points to late October or early November 2026 for the next report. It will show whether revenue growth continues.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 4, 2026 | −$0.13 | −$0.37 | −174.68% | $169.6M | SEC |
| Q1 2026 | May 4, 2026 | −$0.24 | −$0.40 | −65.29% | $127.2M | SEC |
| Q4 2025 | Feb 19, 2026 | $0.00 | $0.03 | +1150.00% | $129.7M | SEC |
| Q3 2025 | Oct 30, 2025 | −$0.30 | $0.28 | +192.20% | $164.9M | SEC |
| Q2 2025 | Aug 6, 2025 | −$0.31 | −$0.14 | +55.09% | $94.8M | SEC |
| Q1 2025 | May 1, 2025 | −$0.57 | −$0.47 | +17.11% | $75.9M | SEC |
| Q4 2024 | Feb 20, 2025 | −$0.56 | −$0.73 | −29.89% | $73.5M | SEC |
| Q3 2024 | Oct 31, 2024 | −$0.67 | −$0.70 | −4.62% | $62.9M | SEC |
| Q2 2024 | Aug 1, 2024 | −$0.79 | −$0.91 | −15.04% | $54.1M | SEC |
| Q1 2024 | May 6, 2024 | −$0.96 | −$1.76 | −83.60% | $41.4M | SEC |
| Q4 2023 | Feb 15, 2024 | −$1.16 | −$1.18 | −1.94% | $45.1M | SEC |
| Q3 2023 | Nov 7, 2023 | −$1.06 | $1.97 | +285.08% | $33.9M | SEC |
| Q2 2023 | Aug 3, 2023 | −$1.09 | −$1.13 | −3.80% | $57.0M | SEC |
| Q1 2023 | May 4, 2023 | −$1.20 | −$1.27 | −5.77% | $57.0M | SEC |
| Q4 2022 | Feb 23, 2023 | −$1.13 | −$1.03 | +9.17% | $55.9M | SEC |
| Q3 2022 | Oct 27, 2022 | −$0.95 | −$1.09 | −15.00% | $53.5M | SEC |
| Q2 2022 | Aug 4, 2022 | −$0.94 | −$1.05 | −11.83% | $51.0M | SEC |
| Q1 2022 | May 5, 2022 | −$0.87 | −$1.20 | −37.93% | $48.5M | SEC |
| Q4 2021 | Feb 24, 2022 | −$0.74 | −$0.84 | −14.18% | $57.2M | SEC |
| Q3 2021 | Oct 28, 2021 | −$0.56 | −$0.59 | −5.04% | $68.2M | SEC |
Quarterly revenue
Frequently asked questions
When did Travere Therapeutics (TVTX) last report earnings?
Travere Therapeutics last reported on Aug 4, 2026, covering fiscal Q2 2026.
Did TVTX beat earnings estimates?
No. Travere Therapeutics reported EPS of −$0.37 for Q2 2026 against a −$0.13 estimate — a 174.68% miss.
How much revenue did TVTX report last quarter?
Travere Therapeutics reported $169.6M in revenue for Q2 2026, against a consensus estimate of $157.3M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.